Welcome to our dedicated page for Pyxus Internatio SEC filings (Ticker: PYYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pyxus International, Inc. (PYYX) SEC filings page brings together the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents provide detailed information on Pyxus’ operations as a global value-added agricultural company, its financial performance, risk factors and capital structure.
In its filings and related press releases, Pyxus reports on sales and other operating revenues, gross profit, gross margin, operating income, net income or loss and non-GAAP measures such as EBITDA, Adjusted EBITDA, Adjusted Free Cash Flow and Net Debt. The company includes reconciliations of non-GAAP metrics to GAAP figures in tables attached to its filings and earnings releases, allowing readers to see how these measures are derived.
Pyxus’ SEC documents and furnished exhibits also describe its inventory position, including tobacco inventory and uncommitted processed inventory, and discuss its operating cycle and working capital management. Capital structure details, such as long-term debt levels, leverage ratios and the terms of credit facilities like its asset-based lending agreement with PNC Bank, appear in these materials and help explain how the company finances its inventory-intensive business.
Current reports on Form 8-K, such as the November 12, 2025 filing, may include or reference press releases announcing quarterly results and other material events. These filings also confirm that Pyxus has no securities listed on a national securities exchange, with its common stock trading on the OTC Pink market under the symbol PYYX.
On Stock Titan, AI-powered tools can help summarize lengthy Pyxus filings, highlight key sections on performance, liquidity, risk factors and capital resources, and make it easier to navigate references to non-GAAP measures and inventory metrics that are central to understanding the company’s disclosures.
Pyxus International reported strong third quarter fiscal 2026 results, highlighted by net income of $16.9 million and adjusted EBITDA of $80.0 million, essentially matching last year’s record third quarter performance. Management reiterated that the company remains on track for one of its strongest years.
Third quarter sales and other operating revenues were $655.8 million, down from $778.3 million, mainly due to shipment timing in Africa and Europe and lower average pricing in South America tied to lower crop purchase costs. Despite lower revenue, gross margin improved to 15.2% from 15.0%, helped by larger South American crops and higher third‑party processing volumes.
For the first three quarters, sales were $1.73 billion, a 12.4% decline from $1.98 billion, while gross margin rose to 14.6% from 13.9%. Tobacco inventory increased to $959.8 million, in line with larger crops, and net debt rose by $199.4 million versus the prior year, with no outstanding borrowings on the $150.0 million ABL facility. Pyxus reaffirmed full‑year fiscal 2026 guidance, targeting net sales of $2.4–$2.6 billion and adjusted EBITDA of $215–$235 million.
Pyxus International, Inc. reported lower sales but stable quarterly profitability in its latest period. For the three months ended December 31, 2025, sales and other operating revenues fell 15.7% to $655.8 million, mainly from lower leaf tobacco volumes and prices, while gross margin ticked up to 15.2% due to favorable mix and stronger processing revenues.
Quarterly net income attributable to Pyxus was $16.9 million, down 10.6% from the prior year, but year-to-date profit dropped sharply to $0.2 million from $20.3 million as lower volumes, shipment timing and higher other expenses weighed on results. Operating cash flow was deeply negative at $(518.6) million for the nine-month period, driven by a large build in inventories and advances to suppliers tied to bigger crops.
Net debt rose to $1.16 billion, up from $960.0 million a year earlier, as the company relied more heavily on foreign seasonal lines of credit. Total tobacco inventories reached $959.8 million as of December 31, 2025, positioning Pyxus to support anticipated higher shipments later in the fiscal year but increasing working capital intensity and leverage.
Pyxus International, Inc. (PYYX) reported a new equity award to one of its directors. On November 20, 2025, the director received 10,980 restricted stock units (RSUs), each representing a contingent right to receive one share of Pyxus common stock.
The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the commencement of the 2026 annual shareholders meeting, with a prorated amount earned if service ends earlier. Vesting is further contingent on the earliest of March 31, 2031, a defined Change in Control transaction, or Pyxus common stock being listed for trading on a registered or approved foreign securities exchange. Following this grant, the director beneficially owns 10,980 derivative securities directly.
Pyxus International, Inc. (PYYX) reported a director equity award of 10,980 restricted stock units (RSUs). Each RSU represents a right to receive one share of Pyxus common stock.
The RSUs were granted on November 20, 2025 and are earned based on continued board service through the earlier of August 14, 2026 or the company’s 2026 annual shareholders meeting, with prorated earning if service ends sooner. Vesting is further contingent on the earliest of March 31, 2031, a qualifying change in control transaction, or Pyxus common stock becoming listed for trading on a registered U.S. or approved foreign securities exchange.
Pyxus International, Inc. reported an equity grant to one of its directors in the form of 10,980 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Pyxus common stock at a future date.
The RSUs were awarded on November 20, 2025 and are to be earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the 2026 annual shareholders meeting, with prorated vesting if service ends earlier. Vesting is further contingent on the earliest of March 31, 2031, a defined change in control transaction, or the company’s common stock becoming listed on a registered or approved securities exchange.
Pyxus International, Inc. (PYYX) disclosed that one of its directors received 10,980 restricted stock units (RSUs) on November 20, 2025. Each RSU represents a contingent right to receive one share of Pyxus common stock at no exercise price.
The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the company’s 2026 annual shareholders meeting, with a prorated amount earned if service ends earlier. Actual vesting is further contingent on the earliest of March 31, 2031, a qualifying change in control transaction under the company’s 2020 Incentive Plan, or Pyxus common stock becoming listed for trading on a registered or approved securities exchange.
Pyxus International, Inc. (PYYX) reported an equity compensation grant to one of its directors. On November 20, 2025, the director received 10,980 restricted stock units (RSUs), each representing a contingent right to receive one share of Pyxus common stock. The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the 2026 annual shareholders meeting, with prorated earning if service ends earlier.
Actual vesting is further contingent on the earliest of three events: March 31, 2031; a qualifying Change in Control under the company’s 2020 Incentive Plan; or Pyxus common stock being listed for trading on a U.S. or approved foreign securities exchange.
Pyxus International, Inc. furnished an 8-K announcing it issued a press release with operating and financial results for the three and six months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is furnished, not filed under Section 18 of the Exchange Act. The report lists no securities registered under Section 12(b). The date of the report and press release is November 12, 2025.
Pyxus International filed its 10‑Q reporting Q2 FY2026 results. Sales and other operating revenues were $570.2 million, up 0.7% year over year, as higher volumes and processing revenues offset lower average sales prices. Gross margin improved to 15.4% from 13.3%, and operating income rose to $46.7 million. After $37.9 million of interest expense and $10.3 million of income tax expense, the company reported a net loss of $0.9 million, or $(0.03) per share.
For the first six months, sales were $1,079.0 million, down 10.2%, with a net loss of $16.7 million. Working capital peaked seasonally: inventories increased to $1,135.2 million, and notes payable rose to $908.0 million. Net cash used in operating activities was $580.9 million, reflecting procurement in Africa and South America and timing of shipments. Long‑term debt was $455.3 million and the company remained in compliance with covenants.
The ABL Credit Facility was amended on May 12, 2025 to increase commitments to $150 million and extend maturity to 2030, and two receivables securitization programs remained active. As of October 31, 2025, common shares outstanding were 24,607,791.